SCHEMBL18975035

SCHEMBL18975035

OCc1cnc(C2CC2)s1

nearest known ligand 0.33

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.33
TYRO3 Q06418 1/20 0.33
MERTK Q12866 1/20 0.33
GAS6 Q14393 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
MLYCD O95822 2/20 0.32
PDE10A Q9Y233 1/20 0.32
SLC5A2 P31639 1/20 0.31
ALDH1A1 P00352 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
PKM P14618 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17282699 0.92 WDR5 (0.34) FLT3TYRO3MERTKGAS6HRH3
SCHEMBL16552392 0.91 KMT2A (0.36) ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL21299225 0.85 ALDH1A1 (0.34) FLT3TYRO3MERTKGAS6HRH3
SCHEMBL19984737 0.82 TRPV3 (0.34) PDE10A
SCHEMBL21381142 0.81 HRH3 (0.38) HRH3MLYCDNPC1RAB9ASMN1; SMN2
SCHEMBL7981779 0.80 PDE10A (0.35) PDE10AALDH1A1NPC1RAB9A
SCHEMBL19975174 0.79 SLC5A2 (0.33) FLT3TYRO3MERTKGAS6HRH3
SCHEMBL2898435 0.77 FLT3 (0.32) FLT3TYRO3MERTKGAS6SLC5A2
SCHEMBL19975015 0.74 GPR119 (0.46) HRH3SMN1; SMN2
SCHEMBL23137870 0.73 KDM4E (0.37) PDE10ASLC5A2ALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112574230-B Peptidyl arginine deiminase inhibitors and uses thereof 药捷安康(南京)科技股份有限公司 2022-10-28 CN disclosed
WO-2021057910-A1 PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF 南京药捷安康生物科技有限公司 2021-04-01 WO disclosed
CN-112574230-A Peptidyl arginine deiminase inhibitors and uses thereof 南京药捷安康生物科技有限公司 2021-03-30 CN disclosed
EP-3388425-B1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LTD (JP) 2020-08-05 EP disclosed
US-10689354-B2 Aminoazole derivative TEIJIN PHARMA LIMITED (JP) 2020-06-23 US disclosed
US-20190031628-A1 AMINOAZOLE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2019-01-31 US disclosed
WO-2017099237-A1 AMINOAZOLE DERIVATIVE 帝人ファーマ株式会社 2017-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689354-B2 Aminoazole derivative AR, NR3C2, NR5A1 FLT3 947/4885TYRO3 268/4885MERTK 1835/4885
US-20190031628-A1 AMINOAZOLE DERIVATIVE AR, NR3C2, NR5A1 FLT3 947/4885TYRO3 268/4885MERTK 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.